34.56
Avidity Biosciences Inc stock is traded at $34.56, with a volume of 3.34M.
It is down -4.71% in the last 24 hours and up +19.05% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$36.27
Open:
$36.5
24h Volume:
3.34M
Relative Volume:
2.01
Market Cap:
$4.17B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-11.96
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
+1.59%
1M Performance:
+19.05%
6M Performance:
+7.73%
1Y Performance:
-28.21%
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RNA
Avidity Biosciences Inc
|
34.56 | 4.37B | 10.12M | -280.49M | -188.51M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-10-25 | Resumed | Goldman | Buy |
Jun-24-25 | Initiated | Bernstein | Outperform |
Jun-17-25 | Initiated | Wolfe Research | Outperform |
Jun-11-25 | Initiated | Raymond James | Strong Buy |
Mar-13-25 | Initiated | Citigroup | Buy |
Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Dec-20-24 | Initiated | H.C. Wainwright | Buy |
Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
Sep-24-24 | Initiated | Goldman | Buy |
Aug-28-24 | Initiated | Barclays | Overweight |
May-03-24 | Initiated | BofA Securities | Buy |
Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
Jul-12-22 | Initiated | Raymond James | Strong Buy |
Sep-07-21 | Initiated | Evercore ISI | Outperform |
Jun-17-21 | Initiated | Needham | Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Jul-07-20 | Initiated | Cowen | Outperform |
Jul-07-20 | Initiated | Credit Suisse | Outperform |
Jul-07-20 | Initiated | SVB Leerink | Outperform |
Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Trendline Breach Raises Concern for Avidity Biosciences Inc. InvestorsStable Entry High Return Opportunities in Focus - metal.it
Avidity Biosciences and the Potential for First-in-Class DM1 Therapy - AInvest
Avidity completes enrollment for phase 3 trial of DM1 treatment By Investing.com - Investing.com South Africa
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission - PR Newswire
What is the dividend policy of Avidity Biosciences Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com
What are the technical indicators suggesting about Avidity Biosciences Inc.Capitalize on fast-growing stocks today - jammulinksnews.com
How volatile is Avidity Biosciences Inc. stock compared to the marketMaximize your returns with portfolio optimization - jammulinksnews.com
Should I hold or sell Avidity Biosciences Inc. stock in 2025Get alerts on the hottest market movers - jammulinksnews.com
How does Avidity Biosciences Inc. generate profit in a changing economyMassive stock growth - jammulinksnews.com
Is it the right time to buy Avidity Biosciences Inc. stockExpert guidance for superior capital growth - jammulinksnews.com
What institutional investors are buying Avidity Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com
What makes Avidity Biosciences Inc. stock price move sharplyUnlock exclusive stock analysis for investors - jammulinksnews.com
Why is Avidity Biosciences Inc. stock attracting strong analyst attentionExtraordinary earning power - jammulinksnews.com
What are analysts’ price targets for Avidity Biosciences Inc. in the next 12 monthsDiscover stocks with superior performance - jammulinksnews.com
Avidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation - Insider Monkey
Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN
Is Avidity Biosciences Inc. a good long term investmentFree Stock Market Trend Analysis - PrintWeekIndia
Avidity’s Stock Surge: Time to Act? - timothysykes.com
What drives Avidity Biosciences Inc. stock priceFree Wealth Planning Blueprint - PrintWeekIndia
How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com
Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest
Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks
Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru
Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha
FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - ETX View
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):